Circulating Tumor Cell Counts Are Prognostic of Overall Survival in SWOG S0421: A Phase III Trial of Docetaxel With or Without Atrasentan for Metastatic Castration-Resistant Prostate Cancer
Top Cited Papers
- 10 April 2014
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 32 (11), 1136-1142
- https://doi.org/10.1200/jco.2013.51.7417
Abstract
Purpose Circulating tumor cell (CTC) enumeration has not been prospectively validated in standard first-line docetaxel treatment for metastatic castration-resistant prostate cancer. We assessed the...Keywords
This publication has 29 references indexed in Scilit:
- Increased Survival with Enzalutamide in Prostate Cancer after ChemotherapyNew England Journal of Medicine, 2012
- Biomarkers in the Management and Treatment of Men with Metastatic Castration-Resistant Prostate CancerEuropean Urology, 2011
- Circulating Tumor Cells as a Predictive Biomarker in Patients With Hormone-sensitive Prostate CancerClinical Genitourinary Cancer, 2011
- TMPRSS2-ERG Status in Circulating Tumor Cells as a Predictive Biomarker of Sensitivity in Castration-Resistant Prostate Cancer Patients Treated With Abiraterone AcetateEuropean Urology, 2011
- Portable Filter-Based Microdevice for Detection and Characterization of Circulating Tumor CellsClinical Cancer Research, 2010
- A Cancer Detection Platform Which Measures Telomerase Activity from Live Circulating Tumor Cells Captured on a MicrofilterCancer Research, 2010
- Prostate-Specific Antigen Progression Predicts Overall Survival in Patients With Metastatic Prostate Cancer: Data from Southwest Oncology Group Trials 9346 (Intergroup Study 0162) and 9916Journal of Clinical Oncology, 2009
- Circulating tumour cells as prognostic markers in progressive, castration-resistant prostate cancer: a reanalysis of IMMC38 trial dataThe Lancet Oncology, 2009
- Circulating Tumor Cells, Disease Progression, and Survival in Metastatic Breast CancerNew England Journal of Medicine, 2004
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI Journal of the National Cancer Institute, 2000